NEW YORK – BGI said last week that its nucleic acid detection kit for bloodstream infection pathogens has received the CE mark.
The kit, developed by BGI Patho-Genesis Pharmaceutical Technology, a holding subsidiary of BGI Genomics, uses combinatorial probe-anchor synthesis technology to prepare libraries for metagenomic sequencing to detect pathogens that cause bloodstream infections. It is designed to construct a sequencing library directly from clinical samples.